post neoadjuvant management in brca mutant breast cancer patients
Published 1 year ago • 12 plays • Length 4:41Download video MP4
Download video MP3
Similar videos
-
3:01
asco: neoadjuvant therapy with cisplatin in brca1-positive breast cancer patients
-
4:56
neoadjuvant talazoparib active in brca-mutated early breast cancer | jennifer litton
-
1:56
axillary management for breast cancer in the post-neoadjuvant setting
-
2:03
preoperative management of operable ct3 cn1 luminal breast cancer: upfront neoadjuvant chemotherapy
-
3:03
sequencing in brca-positive tnbc patients
-
14:51
breast cancer neoadjuvant chemotherapy: for patients
-
1:59
effectiveness of icis in the neoadjuvant and post-neoadjuvant breast cancer setting
-
2:02
dr. litton on a study of neoadjuvant talazoparib for patients with brca-mutated tnbc
-
7:22
residual cancer burden after neoadjuvant therapy and long-term survival outcomes in breast cancer
-
45:18
management of challenging breast findings including assessment after neoadjuvant systemic therapy
-
6:01
neoadjuvant talazoparib for brca 1/2 mutated triple negative breast cancer
-
0:55
neoadjuvant treatment approach for her2 positive breast cancer
-
36:42
evaluation of breast specimens after neoadjuvant chemotherapy
-
10:28
axillary management of node-positive breast cancer after neoadjuvant chemotherapy
-
3:14
parp inhibitor staves off recurrence in early brca-mutant breast cancer - medpage today
-
10:05
exploring neoadjuvant therapy for breast cancer: what you need to know
-
53:17
brca-positive early-stage breast cancer: treatment and testing
-
1:05
the early breast cancer treatment approach: "neoadjuvant" and "adjuvant"
-
1:24
detection of ctdna post neoadjuvant chemo is associated with disease relapse in early breast cancer